Insider buying last 90 days
No open-market insider purchases were filed for HIMS in the last 90 days.
From Form 4 filings, dated to when each was filed.
Every HIMS insider filing, plotted on the chart in Gekko.Open HIMS in Gekko
NYSE: HIMS
Hims & Hers Health (HIMS) Stock Analysis & Forecast
Sep 28 close
$28.78−0.64 (−2.2%)
Gekko Brief
AI summaryThis week's news centers on a wave of securities class action filings and law firm reminders tied to an FTC lawsuit that accuses Hims of business misconduct, with multiple firms citing a lead plaintiff deadline of November 2, 2026 and a class period running from August 4, 2025 to July 29, 2026. The commentary concerns litigation exposure rather than new operating developments.
HIMS closes at $28.78, down 2.2%, sitting between its 50-day average of $29.55 and 200-day average of $27.70. The GekkoIndex reads 58.6, placing the stock in the Neutral zone. Price sits 41.6% below Gekko Fair Value of $49.25. Over the past month the stock is down 9.1%, though it remains up 48.5% over six months and down 47.5% over the past year.
Earnings are scheduled for 9 November 2026, after the close, 41 days out and beyond a typical 20-day holding window; the last report showed an EPS miss versus estimate and a 3.4% reaction. Options activity shows 5 unusual signals over the past 30 days, with call premium of $2.8 million against put premium of $1.2 million. Analyst consensus among 14 firms includes 3 buy and 11 hold ratings, with a consensus target of $31.15. Seasonality over 5 years shows a 20-day average return of -5.6% from this point, positive in 1 of those years, a factor worth noting alongside the pending litigation deadline.
Written by AI and checked automatically against the figures on this page. Generated Sep 29, 2026 from the data above.
Hims & Hers Health price vs fair value
Close $28.78200-day averageGekko Fair Value $49.25
Hims & Hers Health quick facts
- Market cap
- $6.42B
- P/E ratio
- —
- Forward P/E
- 73.5
- EPS, TTM
- −$0.64
- Revenue, TTM
- $2.58B
- Profit margin
- -5.5%
- Dividend yield
- —
- Beta
- 2.41
- Volume
- 6.46M avg 9.24M
- 1-year return
- −47.5%
- Typical daily move
- ±5.3%
- Typical 20-day move
- ±16.1%
- 50-day average
- $29.55
- 200-day average
- $27.70
- Next earnings
- Nov 9 after close
- Shares outstanding
- 224.9M
Hims & Hers Health swing-trade checklist
Hims & Hers Health scores 3 supportive, 2 mixed and 1 headwind across the 6 checklist items with data.
Six things swing traders check before a 20-day hold, read from the latest data.
3 supportive2 mixed1 headwind
- Trendmixed
Averages disagree
Close $28.78 sits between the 50-day ($29.55) and 200-day ($27.70) averages, or the averages disagree.
See the chart - GekkoIndexmixed
58.6, Neutral
Reading 58.6 is in the Neutral zone.
See the GekkoIndex - Fair valuesupportive
41.6% below
Price is 41.6% below Gekko Fair Value (more than 5% below).
See fair value - Smart moneysupportive
Leans bullish
Last 30 days: 5 unusual options signals.
See smart money - Earnings risksupportive
Reports in 41 days
Next report Nov 9, 2026, 41 days away — outside a typical 20-trading-day hold.
See earnings - Seasonalityheadwind
−5.6% on average
From this point in the calendar, the next 20 trading days averaged −5.6% over 5 years, rising in 1 of them.
See seasonality
A description of current data, not a recommendation. How this page works
Hims & Hers Health stock chart and price history
Hims & Hers Health closed at $28.78 on Sep 28, 2026, −47.5% over the past year, inside a 52-week range of $13.74 to $65.30.
Close50-day average200-day averageVolume
Use the left and right arrow keys to read daily values.
Performance Breakdown
- 1 month
- −9.1%
- 3 months
- −13.8%
- 6 months
- +48.5%
- 1 year
- −47.5%
The full HIMS chart adds GekkoIndex, insider, options, Congress and hedge fund markers, plus TrendCandles™.Open HIMS in Gekko
Follow Hims & Hers Health through every session
Put HIMS on a Gekko watchlist and see its GekkoIndex, Gekko Fair Value and smart money signals update on the chart as they change.
Track HIMS in GekkoFree for 7 days. No credit card required.
Hims & Hers Health GekkoIndex: the smart money zone
Hims & Hers Health’s GekkoIndex — Gekko’s 0 to 100 smart money score — reads 58.6, in the Neutral zone, down 0.4 points over five sessions.
58.6Neutral
Down 0.4 points over five sessions.
Reading for Sep 28, 2026
What followed past readings in each zone
| Zone | Readings | 5 days | 20 days |
|---|---|---|---|
| Buying | 46 | −2.5% | +10.3% |
| Accumulation | 215 | +1.7% | +14.0% |
| Neutral (current zone) | 346 | +2.2% | +5.6% |
| Distribution | 54 | +4.9% | +4.7% |
| Selling | 11 | −0.1% | −3.2% |
Average HIMS share-price change over the trading days after each daily reading in its GekkoIndex history. Across every stock Gekko tracks, Neutral readings averaged +1.1% over 20 days. Past behaviour doesn’t guarantee future results.
Neutral zone: No clear directional signal. About the five zones →
See every daily GekkoIndex reading plotted over the HIMS price, zone by zone.Track HIMS in Gekko
Is Hims & Hers Health stock overvalued? Gekko Fair Value
Hims & Hers Health trades 41.6% below Gekko Fair Value of $49.25, so the shares are undervalued on Gekko’s estimate.
Gekko’s own estimate of what Hims & Hers Health shares are worth, recalculated every trading day.
$49.25
Gekko Fair Value, Sep 29, 2026
41.6% Undervalued
Gekko Fair Value on every chart, with the gap to price updating daily.Open HIMS in Gekko
Hims & Hers Health insider and Congress trading
No open-market insider purchases were filed for Hims & Hers Health, and no Congress trades were disclosed, in the last 90 days.
Plus buybacks, unusual options and fund positions, each dated to when it became public.
Congress trades last 90 days
No trades in HIMS were disclosed by members of Congress in the last 90 days.
From congressional disclosures, which report amounts as ranges.
Congress disclosures for HIMS, plotted on the chart in Gekko.Open HIMS in Gekko
Buybacks
Hims & Hers Health has been buying back its own shares.
- Bought back, quarter ended Jun 30, 2026
- $23.07M
- As a share of market cap
- 0.36%
From company filings.
Unusual options activity last 30 days
5signals, 70% of the flagged premium in calls.
Latest: Bullish flow on Sep 26, $1.58M in unusual premium.
Hedge funds and billionaires quarter ended Jun 30
4of the funds Gekko tracks hold HIMS.
0added4opened0trimmed0sold out
Every signal with its contract, strike and premium, and which funds are on each side.Unlock in Gekko
Hims & Hers Health earnings: next date and track record
Hims & Hers Health reports on Nov 9, 2026, after the close (41 days away), and beat the EPS estimate in 3 of its last 8 reports.
Next earnings report
Nov 9, 2026
Expected after the close, 41 days away
- EPS estimate
- $0.07
- Revenue estimate
- $892.6M
3 of 8reports beat the EPS estimate
±9.4%average move across the report
2 of 8reports followed by a gain
Share-price move across each report
Last earnings call, Aug 10, 2026 AI summary
- What they said
- Hims & Hers reported strong Q2 2026 results with revenue growing nearly 40% year-over-year to more than $753 million and ending the quarter with nearly 3 million subscribers (adding ~300,000 net new subscribers). Domestic revenue accelerated to $622 million (16% YoY). Management emphasized three growth drivers: investment in AI/technology (improving engagement and operational efficiency), an infrastructure enabling expansion into more complex care categories (notably testosterone replacement therapy and weight loss), and international expansion bolstered by the Eucalyptus acquisition (~$40 million of revenue in Q2). The company highlighted early AI wins (Hers weight loss rollout: 3x messages, AI answers ~80% of questions, ~50% reduction in nonclinical tasks), the rapid scaling of testosterone offerings (approaching a $100M run-rate in multiple categories), and strategic partnerships (notably with Novo Nordisk on weight-loss therapies). Management described ongoing investments in AI and international markets, preparation for peptide/wellness offerings pending FDA rulemaking, planned expansion into injectable and oral TRT by year-end, and a longer-term vision for a unified AI-native care platform that could underpin membership/freemium offerings within 1–2 years. The call balanced strong growth and clear operational progress with candid discussion of regulatory timelines and near-term reinvestment-driven margin impacts.
- Guidance
- Management said they elevated guidance for the remainder of the year (citing stronger-than-expected weight category performance) and expect acceleration in revenue and EBITDA in the back half of the year. Specific near-term timing guidance: rollout of AI-native experiences across more categories in the coming quarters; peptide/wellness (sermorelin, glutathione, NAD+, other injections) offerings expected to launch potentially by the end of this year (subject to FDA rulemaking); injectable and oral TRT expected before the end of this year; exploration of membership/freemium offerings within 1–2 years. Eucalyptus revenue (~$40M) was included in Q2 results. Management reiterated a long-term target reference (discussed by analysts) of ~20% margins by 2030 but did not provide firm multi-year financial guidance for FY2027 in this call.
- Risks flagged
- Regulatory uncertainty around peptides and dependence on FDA rulemaking; near-term margin/EBITDA pressure from investments in AI and international expansion; reliance on partnerships with large drug manufacturers (e.g., Novo Nordisk) and potential supply-chain/manufacturing execution risks (e.g., API facility validation); competition in weight-loss/metabolic categories and potential volatility in demand; general macro and execution risks described in safety-harbor/SEC disclosures.
| Reported | EPS | Revenue | Move |
|---|---|---|---|
| Aug 10, 2026 | −$0.10 est −$0.07 | $753.2M est $698.9M | −3.4% |
| May 11, 2026 | −$0.40 est $0.13 | $608.1M est $616.8M | −11.5% |
| Feb 23, 2026 | $0.07 est $0.02 | $617.8M est $619.2M | −1.1% |
| Nov 3, 2025 | $0.06 est $0.09 | $599.0M est $618.1M | −5.9% |
| Aug 4, 2025 | $0.17 est $0.18 | $544.8M est $584.1M | −11.2% |
| May 5, 2025 | $0.20 est $0.12 | $586.0M est $538.6M | +21.2% |
| Feb 24, 2025 | $0.11 est $0.22 | $481.1M est $494.6M | −19.1% |
| Nov 4, 2024 | $0.32 est $0.04 | $401.6M est $469.5M | +1.4% |
“Move” is the close of the first session after the report compared with the close of the last session before it, so it reads the same whether the company reported before the open or after the close.
Hims & Hers Health stock forecast and analyst price targets
Analysts’ average 12-month price target for Hims & Hers Health is $31.15, +8.2% from the last close, from 14 firms rating the stock in the last 90 days.
$31.15consensus 12-month target, +8.2% from the last close
Now $28.78Avg $31.15
Low $26High $42
Each firm’s latest rating in the last 90 days: 14 firms.
Latest analyst actions
| Date | Firm | Target | vs price |
|---|---|---|---|
| Sep 25 | Bank of America Securities | $32 | +11.2% |
| Sep 15 | Bank of America Securities | $32 | +11.2% |
| Sep 11 | J.P. Morgan | $32 | +11.2% |
| Sep 11 | Truist Financial | $32 | +11.2% |
| Sep 3 | Jefferies | $31 | +7.7% |
+5.6%average 20-day move after past Neutral readings
−5.6%average move over the next 20 trading days in the last 5 years
±5.3%typical daily move, from the 14-day average range
Gekko doesn’t publish price predictions. These are analyst targets and historical base rates, which don’t guarantee future results.
Hims & Hers Health seasonality: the next 20 trading days
Over the next 20 trading days from Sep 29, Hims & Hers Health averaged −5.6% across the last 5 years, rising in 1 of them.
Next 20 trading days, by year
Average move and hit rate
| Window | Average | Years higher |
|---|---|---|
| Next 5 trading days | −1.6% | 2 of 5 |
| Next 10 trading days | −0.6% | 2 of 5 |
| Next 15 trading days | −1.3% | 2 of 5 |
| Next 20 trading days | −5.6% | 1 of 5 |
| Next 30 trading days | +5.2% | 4 of 5 |
For scale, HIMS’s typical 20-trading-day move in either direction is about 16.1%.
Hims & Hers Health market cap and key statistics
Hims & Hers Health’s market cap is $6.42B and revenue of $2.58B over the last twelve months.
Valuation
- Market cap
- $6.42B
- Forward P/E
- 73.5
- EPS, TTM
- −$0.64
- Gekko Fair Value
- $49.25
Trading
- Volume
- 6.46M
- Avg volume, 20 days
- 9.24M
- 52-week high
- $65.30
- 52-week low
- $13.74
- Shares outstanding
- 224.9M
Financials
- Revenue, TTM
- $2.58B
- Profit margin
- -5.5%
- Return on equity
- -32%
- Quarterly earnings growth, YoY
- −17.4%
Risk and income
- Beta
- 2.41
- Typical daily move
- ±5.3%
- Typical 20-day move
- ±16.1%
Hims & Hers Health stock news this week
Coverage of Hims & Hers Health this week reads negative: 0 positive, 1 neutral and 9 negative headlines.
- ROSEN, TOP RANKED GLOBAL COUNSEL, Encourages Hims & Hers Health, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - HIMSNewsfile Corp, Sep 28
- ROSEN, A LEADING NATIONAL FIRM, Encourages Hims & Hers Health, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - HIMSGlobeNewsWire, Sep 28
- Hims & Hers Health (HIMS) Faces Securities Class Action After FTC Lawsuit Reveal Drives Stock Sharply Lower -- HBSSNewsfile Corp, Sep 28
- Kaplan Fox Alerts Hims & Hers Health, Inc. (HIMS) Investors to a Securities Fraud Lawsuit - Lead Plaintiff Deadline Is November 2, 2026Newsfile Corp, Sep 28
- HIMS DEADLINE ALERT: Faruqi & Faruqi, LLP Reminds Hims Investors of Securities Class Action Lawsuit Deadline on November 2, 2026Newsfile Corp, Sep 28
- Kaplan Fox Reminds Investors of Hims & Hers Health, Inc. (NYSE: HIMS) to a Securities Class Action Deadline – Contact the Firm Before November 2, 2026GlobeNewsWire, Sep 28
Hims & Hers Health peers
Hims & Hers Health’s 6 largest industry peers by market value, with today’s move, GekkoIndex zone and gap to Gekko Fair Value.
| Stock | GekkoIndex zone | vs Fair Value |
|---|---|---|
| LHLabcorp | Accumulation | 3.9% below |
| GHGuardant Health | Neutral | 0.5% above |
| SOLVSolventum | Neutral | 16.4% below |
| EHCEncompass Health | Neutral | 7.6% above |
| DVADaVita | Accumulation | 15.9% below |
| BTSGBrightSpring Health Services | Accumulation | 7.4% below |
A peer links to its own page where one exists.
Hims & Hers Health stock FAQ
What is Hims & Hers Health’s market cap?
Hims & Hers Health’s market cap is $6.42B at the Sep 28, 2026 close of $28.78, with 224.9M shares outstanding.
What is the Hims & Hers Health stock forecast?
The consensus analyst 12-month price target for Hims & Hers Health is $31.15, +8.2% from the last close. Of the 14 firms that rated the stock in the last 90 days, 3 rate it a buy, 11 a hold and 0 a sell. Gekko doesn’t publish price predictions of its own.
Is Hims & Hers Health stock overvalued or undervalued?
On Gekko’s estimate Hims & Hers Health is undervalued: the Sep 28, 2026 close of $28.78 is 41.6% below Gekko Fair Value of $49.25. Gekko Fair Value is recalculated every trading day, and a gap inside 5% either way counts as about fair value.
When does Hims & Hers Health report earnings next?
Hims & Hers Health is expected to report on Nov 9, 2026, after the market closes (41 days away). Analysts expect earnings of $0.07 per share on revenue of $892.6M. Hims & Hers Health beat the earnings estimate in 3 of its last 8 reports, moving 9.4% on average across the report.
What is Hims & Hers Health’s 52-week high and low?
Hims & Hers Health’s 52-week high is $65.30 and its 52-week low is $13.74; it closed at $28.78 on Sep 28, 2026, −47.5% over the past year. Over the last five years the shares peaked at $72.98 on Feb 19, 2025.
Is Hims & Hers Health stock a buy right now?
Gekko describes the data; it does not make buy or sell recommendations. On the swing-trade checklist, 3 of the 6 items with data read as supportive (fair value, smart money and earnings risk), 2 as mixed (trend and gekkoindex) and 1 as a headwind (seasonality). The checklist is a description of current data, not a recommendation.
Is there unusual options activity in Hims & Hers Health?
Gekko flagged 5 unusual options signals in Hims & Hers Health over the last 30 days, with $2.76M of flagged premium in calls and $1.19M in puts. The latest, bullish flow, was on Sep 26, 2026 with $1.58M in unusual premium. The signal-by-signal table is in Gekko.
How this page works
During US trading hours the price at the top of the page is a delayed quote, refreshed every 15 minutes; everything else is rebuilt after each US market close. The GekkoIndex, Gekko Fair Value and the checklist are Gekko’s own, and the Gekko Brief is written by AI from this page’s data and checked against it before it is published. How Gekko’s data works →
See Hims & Hers Health the way Gekko members do
Every GekkoIndex reading, insider trade, options bet and Congress disclosure plotted on the chart, plus the 5,800-name screener and trade planning tools.
Join 1,380 other traders using Gekko
Start Your FREE 7 Day Trial → Every feature unlocked. No credit card required.